US Pharma MarketingAstraZeneca
AstraZeneca Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
MUNICH — AstraZeneca’s oral relaxin agonist was able to improve cardiac function in some, though not all, patients in a mid-stage trial. While the study was only a partial success, this is still a decent showing ...
Source: Endpoints News